Ashley S Cha-Silva, Meghan B Gavaghan, Tobias Bergroth, Ronika Alexander-Parrish, Jingyan Yang, Florin Draica, Jaymin Patel, Denise A Garner, Richard H Stanford, Genevieve Meier, John M McLaughlin, Jennifer L Nguyen
BACKGROUND: Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral drug used to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in patients aged 12 years or older at high risk of progression to severe disease (eg, hospitalization and death). Despite being the preferred option for outpatient treatment in the majority of countries worldwide, NMV/r is currently underutilized in real-world clinical practice. AREAS OF UNCERTAINTY: As numerous real-world studies have described patient outcomes following treatment with NMV/r, this systematic literature review provides a comprehensive summary of evidence on NMV/r effectiveness against hospitalization and mortality further organized by clinically meaningful categories, such as acute versus longer-term follow-up, age, underlying health conditions, and vaccination status, to help inform health care decision making...
May 2024: American Journal of Therapeutics